Premium
Intracardiac Echo‐Guided Radiofrequency Catheter Ablation of Atrial Fibrillation in Patients with Atrial Septal Defect or Patent Foramen Ovale Repair: A Feasibility, Safety, and Efficacy Study
Author(s) -
LAKKIREDDY DHANUNJAYA,
RANGISETTY UMAMAHESH,
PRASAD SUBRAMANYA,
VERMA ATUL,
BIRIA MAZDA,
BERENBOM LOREN,
PIMENTEL RHEA,
EMERT MARTIN,
ROSAMOND THOMAS,
FAHMY TAMER,
PATEL DIMPI,
BIASE LUIGI DI,
SCHWEIKERT ROBERT,
BURKHARDT DAVID,
NATALE ANDREA
Publication year - 2008
Publication title -
journal of cardiovascular electrophysiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.193
H-Index - 138
eISSN - 1540-8167
pISSN - 1045-3873
DOI - 10.1111/j.1540-8167.2008.01249.x
Subject(s) - medicine , atrial fibrillation , patent foramen ovale , intracardiac injection , interatrial septum , cardiology , catheter ablation , radiofrequency ablation , percutaneous , fossa ovalis , atrial flutter , pulmonary vein , perioperative , surgery , heart septal defect , ablation , left atrium
Patients with atrial septal defect (ASD) are at higher risk for atrial fibrillation (AF) even after repair. Transseptal access in these patients is perceived to be difficult. We describe the feasibility, safety, and efficacy of pulmonary vein antral isolation (PVAI) in these patients. Method: We prospectively compared post‐ASD/patent foramen ovale (PFO) repair patients (group I, n = 45) with age‐gender‐AF type matched controls (group II, n = 45). All the patients underwent PVAI through a double transseptal puncture with a roving circular mapping catheter technique guided by intracardiac echocardiography (ICE). The short‐term (3 months) and long‐term (12 month) failure rates were assessed. Results: In group I, 23 (51%) had percutaneous closure devices and 22 (49%) had a surgical closure. There was no significant difference between group I and II in the baseline characteristics. Intracardiac echo‐guided double transseptal access was obtained in 98% of patients in group I and in 100% of patients in group II. PVAI was performed in all patients, with right atrial flutter ablation in 7 patients in group I and in 4 patients in group II. Over a mean follow‐up of 15 ± 4 months, group I had higher short‐term (18% vs 13%, P = 0.77) and long‐term recurrence (24% vs 18%, P = 0.6) than group II. There was no significant difference in the perioperative complications between the two groups. Echocardiography at 3 months showed interatrial communication in 2 patients in group I and 1 patient in group II, which resolved at 12 months. Conclusion: Percutaneous AF ablation using double transseptal access is feasible, safe, and efficacious in patients with ASD and PFO repairs.